Background. To determine the factors influencing the use of complementary and alternative medicine (CAM) in gynecologic cancer patients and the prevalence and pattern of CAM use. Methods. This was a cross-sectional study of 370 gynecologic cancer patients conducted at the outpatient clinic, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. After obtaining informed consent, participants were asked to complete a standardized questionnaire including sociodemographic and clinical characteristics, detail of CAM use, attitude of CAM use, and quality of life using EORTC-QLQ-C30. Results. The prevalence of CAM use was 25.13%. The most common type was herbal medicine (55.90%). The participants who resided or had a birthplace in rural areas presented with a higher proportion of CAM use than those in urban areas ( P = 0.470 and P = 0.004 , respectively). Participants who received multiple modalities of cancer treatment reported a significantly higher proportion of CAM use ( P = 0.024 ). Most CAM users agreed that the CAM could be used in combination with standard treatment, and some rather disagreed that CAM could interrupt the treatment effect of the conventional treatment. CAM users had significantly higher role functioning in quality-of-life scores. Conclusion. Factors influencing CAM use in gynecologic cancer patients were rural area birthplace or residency, receiving multiple modalities of cancer treatment, having positive attitude toward CAM use. CAM users had better performance in role functioning in the quality-of-life score. Therefore, gynecologic oncologists should pay attention to these factors in order to communicate with gynecologic cancer patients about CAM use.
Contents surgery (CRS) improved survival in selected patients with peritoneal carcinomatosis, although the procedures are associated with high morbidity and mortality rates. This study investigated the morbidity and mortality rate of CRS with HIPEC in patients with gynecologic cancers. Methods: We reviewed retrospectively the medical records of patients who underwent CRS with HIPEC due to gynecologic cancer and pseudomyxoma peritonei from January 2013 to June 2021 at 2 institutions in Korea. The adverse events (AEs) that occurred within 60 days of HIPEC and operative factors related to the AEs were investigated. Results: A total of 170 procedures were included in this study. There were 155 procedures with ovarian/tubal/peritoneal cancer (91.2%) and 15 (8.8%) with pseudomyxoma peritonei. The median age of patients was 55 years old (range, 16-79). The median score of the peritoneal carcinomatosis index was 9 (range, 0-29). The median operative time was 480 minutes (range, 195-1,080), and estimated blood loss was 600 mL (range, 50-8,600). AE of grade ≥3 during hospitalization occurred in 63 procedures (37.1%). The most common serious AE was anemia (34/170, 20%), followed by neutropenia (4.7%) and ileus (4.1%). The mortality rate was 0.6% (1/170) due to acute myocardial infarction. A total of 29 patients (17.1%) was re-hospitalization due to AEs within 60 days postoperative. Conclusion:The morbidity and mortality rates of CRS with HIPEC in gynecologic cancer patients are comparable with previous reports, and those are in acceptable rates even broad extent of surgery and the long operation time.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.